Lupin shares

Trump’s tariff threats are spooking pharma. Are MNC stocks the answer?

Investors are increasingly turning to ‘safer’ MNC pharma stocks with a domestic focus at a time when the Trump administration…

August 19, 2025 15:49 IST

Lupin signs $50 million biosimilar licensing deal with Zentiva

Lupin inks $50 million licensing deal with Zentiva for global biosimilar rollout

Lupin has signed a $50 million licensing deal with Zentiva for the global commercialization of its biosimilar Certolizumab Pegol, targeting…

July 9, 2025 11:00 IST

Three reasons why pharma stocks are falling today?

Pharma stocks are under significant selling pressure. Here is a detailed analysis on the top worries for the sector.

Updated: March 25, 2025 14:45 IST

Lupin share price today, Lupin share news

Lupin shares gain nearly 2% on strong Q2; Get your prescription for the stock

Lupin shares have shown strong growth, with a 3% return over the past three months and 30.65% over the last…

Updated: November 8, 2024 09:18 IST

Lupin stock rating ‘Accumulate’: 13% upside seen on gSpiriva launch, US market gains; check target price

Elara Capital has set a target price of Rs 992 on Lupin stock, which is an upside of 13%, with…

Updated: June 22, 2023 17:07 IST

Market awaits Lupin’s new product launch

Company anticipates Ebitda margin boost from gSpiriva in August.

May 16, 2023 01:35 IST

Rakesh Jhunjhunwala, Lupin, Fortis Healthcare, The Mandhana Retail Ventures, MCX, TARC

Rakesh Jhunjhunwala exits MCX, cuts stakes in 2 more firms after Lupin, Fortis Healthcare

Rakesh Jhunjhunwala has exited MCX, after trimming his stakes in at least four firms — Lupin, Fortis Healthcare, The Mandhana…

October 18, 2021 15:27 IST

Rakesh Jhunjhunwala trims stake in Fortis Healthcare even as stock rallies over 72% so far this year

Rakesh Jhunjhunwala has cut a stake in a healthcare firm Fortis Healthcare to 4.23 per cent

October 18, 2021 12:03 IST

Rakesh Jhunjhunwala, Lupin, pharma stocks

Rakesh Jhunjhunwala cuts stake in Lupin; stock remains under pressure, loses over 4% so far this year

Rakesh Jhunjhunwala has trimmed stake in pharma major Lupin to below one per cent.

October 14, 2021 12:29 IST

Ami Organics IPO, Ami Organicsgmp, Ami Organics grey market premium

Ami Organics IPO: Stock lists tomorrow, grey market premium strong; analysts see up to 35% listing gains

Ami Organics is scheduled to make its stock market debut on Tuesday, 14 September, after receiving over 64 times subscription…

September 13, 2021 12:26 IST

Rakesh Jhunjhunwala’s favorite stock Lupin tanks 17% in 7 days; should you buy, sell or hold?

Lupin share price fell nearly 2 per cent to Rs 958.70 apiece in intraday deals, following the April-June quarter earnings…

August 16, 2021 13:43 IST

Nifty, Bank Nifty outlook: Nifty to trade in 15,600-15,900 range, Bank Nifty may top 37,000; Infosys in focus

The chart pattern suggests that if Nifty crosses and sustains above 15950 level it would witness buying which would lead…

July 19, 2021 08:46 IST

Buy HDFC, Axis Bank, Lupin, M&M stocks to pocket gains; Nifty support at 15,700-15,750

On Wednesday 15900/15930 (53000/53100) would be major hurdles and support would be at 15730/52500 and 15700/52400 levels.

July 14, 2021 08:53 IST

Rakesh Jhunjhunwala-owned drug stock hits new 52-week high; charts show it may rally up to 20% more

Rakesh Jhunjhunwala-owned Lupin share price surged as high as 4.7 per cent to Rs 1,266.35 apiece in intraday deals on…

June 2, 2021 14:17 IST

Nifty may trade in 14,400-15,000 range this week, Bank Nifty below 20, 50, 100 day SMAs; Wipro, Cipla in focus

The chart pattern suggests that if Bank Nifty crosses and sustains above 33000 level it would witness buying which would…

May 17, 2021 08:34 IST

L&T, Cipla, Lupin, Dr Reddy's, Vedanta, stocks in focus

L&T, Cipla, Lupin, Dr Reddy’s, Vedanta, GAIL, Tata Power, Reliance Infrastructure stocks in focus

Nifty futures were trading 191.50 points or 1.32 per cent higher at 14,699 on Singaporean Exchange, indicating a strong opening…

May 14, 2021 08:17 IST

Lupin reports 18 pc increase in Q4 net profit at Rs 460 cr; FY21 profit at Rs 1,216 cr

The company said its board has recommended a dividend of Rs 6.5 per equity share of the face value of…

May 13, 2021 13:04 IST

sanjiv Bhasin, Nifty, Bank nifty, HDFC Bank, auto sector

Sanjiv Bhasin’s stock picks for next 5 months; sees Nifty at 15,000, Bank Nifty near 34,250 by May-end

Indian share market benchmarks BSE Sensex and Nifty 50 have been witnessing volatility amid the second COVID-19 wave.

May 6, 2021 11:19 IST

Related News

Govt extended ITR AY 2025-26 deadline, but only 4.56 crore returns filed so far

China exits Pakistan’s $60 billion CPEC flagship project; Islamabad turns to ADB for funding

China exits Pakistan’s $60 billion economic corridor project; Islamabad turns to ADB for funding

New Zealand visa application, visa police certificates, visa Regional Passport Office, Indian Ministry of External Affairs, Immigration New Zealand

New Zealand issues new rules for Indian national visa applicants

GST Exemption May Force Health Insurers to Raise Premiums.

Star Health, Niva Bupa may need 1–4% price hike to offset ITC loss

Laura Loomer said that Americans may no longer have to press a number to listen in English when calling customer care as Trump is mulling blocking outsourcing work to Indian IT companies.

Trump mulling blocking IT outsourcing, says Laura Loomer, pushes to ‘make call centres American again’

Why Markets Aren’t Rising Despite GST Cuts

Market14 min ago

The Indian equity market is facing challenges as the Nifty and Sensex remain stagnant and lag behind other emerging markets. Despite positive factors like GDP growth and GST restructuring, investor sentiment is low due to concerns about slow capex allocation, global trade negotiations, US tariffs, and FII selling. A multi-asset investment approach may be beneficial in this situation.

View all shorts